A Study to Evaluate the Efficacy and Safety of Pravastatin/Fenofibrate Complex in Patients With Combined Dyslipidemia With Adequately Controlled LDL-C But Inadequately Controlled Triglyceride Level by Atorvastatin Monotherapy
Phase of Trial: Phase III
Latest Information Update: 04 Sep 2017
At a glance
- Drugs Fenofibrate/pravastatin (Primary) ; Atorvastatin
- Indications Dyslipidaemias
- Focus Registrational; Therapeutic Use
- Acronyms PRADA
- Sponsors Yoo Young Pharmaceutical
- 30 Aug 2017 Planned number of patients changed from 366 to 302.
- 20 Jun 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
- 20 Jun 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.